AstraZeneca sets up cell therapy operations in Lin-gang
UK-based pharmaceutical company AstraZeneca announced the creation of a cell therapy subsidiary in the Lin-gang Special Area during the 9th China International Import Expo (CIIE), held in Shanghai from Nov 5 to 10.

The launch ceremony of AstraZeneca's booth at the 9th CIIE. [Photo/Shanghai Observer]
The move is expected to strengthen AstraZeneca's end-to-end cell therapy operations in China, from R&D to commercial production, while expanding its supply reach across the Asian market.
Earlier this year, the enterprise unveiled plans to invest more than 100 billion yuan ($15 billion) in China by 2030, aiming to expand its pharmaceutical manufacturing and R&D footprint.
Iskra Reic, AstraZeneca's international executive vice president, said China's leading scientific research strengths, advanced manufacturing capacity, and dynamic life sciences innovation ecosystem strengthen the company's confidence in its long-term commitment to the country.
The planned investment reflects this confidence and will further strengthen AstraZeneca's presence across China's pharmaceutical value chain, contribute to the vision of building a Healthy China by 2035, and bring more innovative treatments to patients worldwide, Reic added.
-
Address No 200 Shengang Avenue, Pudong New Area, Shanghai, China
-
Zip Code 201306
-
TEL +86-21-68283063
-
FAX +86-21-68283000




A young Turkmen's day in Lin-gang
Lin-gang unleashed: Innovation at 9th CIIE
A foreign teacher's day in Lin-gang


